c-myc down-regulation induces apoptosis in human cancer cell lines exposed to RPR-115135 (C31H29NO4), a non-peptidomimetic farnesyltransferase inhibitor

Journal of Pharmacology and Experimental Therapeutics

Volumn 304, Issue 1, 2003, Pages 37-47

  Russo, Patrizia ^a   Arzani, Dario ^a,c   Trombino, Sonya ^a   Falugi, Carla ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CASPASE; DNA FRAGMENT; MESSENGER RNA; MYC PROTEIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN FARNESYLTRANSFERASE INHIBITOR; PROTEIN P21; PROTEIN P53; RAS PROTEIN; RPR 115135; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL LINE; CELL PROLIFERATION; CELL STRAIN HL 60; COLON CANCER; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FILTER; GENE MUTATION; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; MORPHOLOGY; ONCOGENE C MYC; ONCOGENE RAS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ALKYL AND ARYL TRANSFERASES; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL SURVIVAL; DNA FRAGMENTATION; DOWN-REGULATION; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; FLOW CYTOMETRY; FLUORESCENT DYES; GENE DELETION; GENES, MYC; GENES, P53; GENES, RAS; HUMANS; INDOLES; ONCOGENE PROTEIN P21(RAS); REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0037215610     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.102.042952     Document Type: Article

References (36)

1. Adjei AA (2001) Blocking oncogenic Ras signaling for cancer therapy. J Natl Cancer Inst 93:1062-1074.
2. Bange J, Zwick E, and Ullrich A (2001) Molecular targets for breast cancer therapy and prevention. Nat Med 7:548-552.
3. Bertrand R, Sarang M, Jenkin J, Kerrigan D, and Pommier Y (1991) Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression. Cancer Res 51:6280-6285.
4. Bos JL (1989) Ras oncogenes in human cancer: A review. Cancer Res 49:4682-4689.
5. Calabretta B, Kaczmarek L, Ming PM, Au F, and Ming SC (1985) Expression of c-myc and other cell cycle-dependent genes in human colon neoplasia. Cancer Res 45:6000-6004.
6. Ceballos E, Delgado MD, Gutierrez P, Richard C, Muller D, Eilers M, Ehinger M, Gullberg U, and Leon J (2000) c-Myc antagonizes the effect of p53 on apoptosis and p21WAF1 transactivation in K562 leukemia cells. Oncogene 19:2194-2204.
7. Chou T-C and Talalay P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252:6438-6442.
8. Chou T-C and Talalay P (1981) Generalized equations for the analysis of inhibitors of Michaelis-Menten and higher order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115:207-216.
9. Crespo NC, Ohkanda J, Yen T, Hamilton AH, and Sebti SM (2001) The farnesyl-transferase inhibitor, FTI-2153, blocks bipolar spindle formation and chromosome alignment and causes prometaphase accumulation during mitosis of human lung cancer cells. J Biol Chem 276:16161-16167.
10. Crul M, de Klerk GJ, Beijnen JH, and Schellens JH (2001) Ras biochemistry and farnesyl transferase inhibitors: a literature survey. Anticancer Drugs 12:163-184.
11. Debernardis D, Graniela Sirè E, de Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, and Broggini M (1977) p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel. Cancer Res 57:870-874.
12. Edamatsu H, Gau CL, Nemoto T, Guo L, and Tamanoi F (2000) Cdk inhibitors, roscovitine and olomoucine, synergize with farnesyltransferase inhibitor (FTI) to induce efficient apoptosis of human cancer cell lines. Oncogene 19:3059-3068.
13. Galderisi U, Di Bernardo G, Cipollaro M, Peluso G, Cascino A, Cotrufo R, and Melone MA (1999) Differentiation and apoptosis ofneuroblastoma cells: Role of N-myc gene product. J Cell Biochem 73:97-105.
14. Gibbs JB (2000) Anticancer drug targets: Growth factors and growth factor signaling. J Clin Investig 105:9-13.
15. Harel-Bellan H, Ferris DK, Vinocour M, Holt JT, and Farrar WL (1988) Specific inhibition of c-myc protein biosynthesis using antisense synthetic deoxyoligonucleotide in human T lymphocytes. J Immunol 140:2431-24355.
16. Hill TH, Perrin D, and Kruczynski L (2000) Inhibition of Ras-targeted prenylation: Protein farnesyl transferase inhibitors revisited. Crit Rev Oncol Hematol 33:7-23.
17. Hung W-C, Chai C-Y, Huang J-S, and Chuang LY (1996) Expression of Cyclin D1 and c-Ki-Ras gene product in human epithelial ovarian tumors. Human Pathol 27:1324-1328.
18. Karp JE, Lancett JE, Kaufman SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kotke TJ, et al. (2001) Current status of clinical trials of farnesyltransferase inhibitors. Blood 97:3361-3369.
19. Katz ME and McCormick F (1997) Signal transduction from multiple Ras effectors. Curr Opin Gen Dev 7:75-79.
20. Koo H-M, Monks A, Mikheev A, Rubistein LV, Gray-Goodrich M, McWilliams MJ, Alvord WG, Oie HK, Gazdar AF, Paull KD, et al. (1996) Enhanced sensitivity to 1-β-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumour cell lines harboring activated ras oncogens. Cancer Res 56:5211-5216.
21. Korsmeyer SJ (1999) BCL-2 gene family and the regulation of programmed cell death. Cancer Res 59 (Suppl 7):1693s-1700s.
22. Lloyd AC (2000) p53: Only ARF the story. Nature Cell Biol 2:E48-E50.
23. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Motho M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, et al. (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Anticancer Drug Screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
24. Ottoboni C, Crippa A, Falugi C, and Russo P (2001) Induction of micronuclei by new non-peptidic mimetic farnesyltransferase inhibitor RPR-115135: Role of gene mutations. Mutagen 16:423-430.
25. Pan Q and Simpson RU (1999) c-myc intron element-binding proteins are required for 1,25-dihydroxyvitamin D3 regulation of c-myc during HL-60 cell differentiation and the involvement of HOXB4. J Biol Chem 274:8437-8444.
26. Purcell WT and Donehower RC (2002) Evolving therapies: Farnesyltransferase inhibitors. Curr Oncol Rep 4:29-36.
27. Russo P, Cimoli G, Valenti M, De Sessa F, Parodi S, and Pommier Y (1994) Induction of DNA double-strand breaks by 8-methoxycaffeine: Cell cycle dependence and comparison with topoisomerase II inhibitors. Carcinogenesis 15:2491-2496.
28. Russo P, Malacarne D, Falugi F, Trombino S, and O'Connor PM (2002a) RPR-115135, a farnesyltransferase inhibitor, increases 5-FU-cytotoxicity in ten human colon cancer cell lines: Role of p53. Int J Cancer 100:266-275.
29. Russo P, Ottoboni C, Crippa A, Riou JF, and O'Connor PM (2002b) The nonpeptidomimetic farnesyltransferase inhibitor RPR-115135 increases cytotoxicity of 5-FU: Role of p53. J Pharmacol Exp Ther 300:220-226.
30. 1 arrest only in serum starved cells. Int J Oncol 18:855-862.
31. Schwartz G, Rowinsky EK, Rha SY, Hammond LA, Smith L, Patnaik A, Hidalgo M, Berg K, Izbicka E, and Tolcher AW (2001) A Phase 1, pharmacokinetic and biologic correlative study of R115777 and Trastuzumah (Herceptin) in patients with advanced cancer. Proc Am Assoc Clin Oncol 20:81a.
32. Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, and Nevins JR (2000) Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev 14:2501-2514.
33. Suzuki N, Urano J, and Tamanoi F (1998) Farnesyltransferase inhibitors induce cytochrome c release and caspase 3 activation preferentially in transformed cells. Proc Natl Acad Sci USA 95:15356-15361.
34. Vikhanskaya F, Clerico L, Valenti M, Stanzione MS, Broggini M, Parodi S, and Russo P (1997) Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: Possible role of p53. Int J Cancer 72:155-159.
35. Waldman T, Kinzler KW, and Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55:5187-5190.
36. ARF gene transfer in human mesothelioma cells. J Natl Cancer Inst 92:636-641.